Open Accessibility Menu

Coronavirus (COVID-19) Vaccine Update Click here to learn more.

For information about COVID-19 or to view additional resources, please click here.

Clinical Trial Information

Phase 3 ALS study (CY 5031) with reldesemtiv. (Cytokinetics)

Study Details

This is a Phase 3, double-blind, randomized, placebo-controlled trial of reldesemtiv in patients aged 18 to 80 with ALS to assess the effect of reldesemtiv versus placebo on functional outcomes in ALS

Primary Sponsor:

Cytokinetics

Prinicipal Investigator:

Dr. Elham Bayat

Contact Phone:

(202) 741-6210
Phase 3 ALS study (CY 5031) with reldesemtiv. (Cytokinetics) raly@mfa.gwu.edu

Interested in More Information

  • Please enter your first name.
  • Please enter your last name.
  • This isn't a valid email address.
    Please enter your email address.
  • This isn't a valid phone number.
    Please enter your phone number.
    You entered an invalid number.
  • Please enter your address.
  • Please enter your city.
  • Please enter your state.
  • Please enter your zip code.
  • (All Uppercase. No Spaces)